Han Sungho
Founder & Chief Executive Officer GENUV, Inc.
Dr. Sungho Han is Founder and CEO of Genuv, a clinical-stage biopharmaceutical company advancing therapies for cancer, immune-related disorders, and neurodegenerative diseases. She leads the company’s platform technologies, strategy, and global partnerships, including the successful out-licensing of a novel oncology immunocytokine and securing ADDF funding for its neurodegenerative program.
With extensive experience spanning R&D, business development, regulatory reform, and intellectual property, Dr. Han has held leadership roles at DNA Link, Medi-Post, and Kim & Chang. She played a key role in advancing Korea’s genomics and gene therapy landscape, contributed to the development of the world’s first approved allogeneic stem cell therapy, and advised global biotech companies on patent strategy. Dr. Han holds a Ph.D. in Anatomy and Neurobiology and is a published researcher in neural regeneration, bringing a unique combination of neuroscience expertise and biotech leadership.
Seminars
- Novel Target Discovery and AI Platform: Unlocking deeper therapeutic insights through the AI-driven discovery of neuroregenerative targets (encompassing neurogenesis, neuroprotection, and synaptogenesis) and the identification of mechanistically driven biomarkers
- First-in-Human Translation in ALS: Translating insights from a First-in-Human (FIH) study evaluating a novel neuroregenerative therapeutic for Amyotrophic Lateral Sclerosis (ALS), while rethinking the clinical utility and limitations of peripheral blood Neurofilament Light (NfL) chain as a general structural marker
- MoA-Specific Biomarkers in Companion Canine Patients: Showcasing the robust translational value of proprietary, mechanism-specific biomarker(s), which directly correlate with disease severity across diverse real-world companion canine patients suffering from natural neurodegenerative diseases
- Strategic Imperatives: Defining actionable clinical development and biomarker strategies to bridge the translational gap, successfully delivering genuine, disease-modifying therapies to patients
